TFDA-2024-0011-V211

Type II variation for application TFDA-2024-0011. Type II variation: Formulation Change for Kcluximab — minor update

Variation Number
TFDA-2024-0011-V211
Type
Type II
Application
TFDA-2024-0011
Change
CHG-2022-0211
Status
Failed
Fee
€21,800
Submitted
2022-09-06
Approved
—
Description

Type II variation: Formulation Change for Kcluximab — minor update